Skip to main content
    I

    iSpecimen Inc (ISPC)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $0.60
    -0.05 (-8.17%)

    Market Cap: $1.66M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    iSpecimen Inc (ISPC) Financials: Revenue, Profit and Cash Flow

    Updated Aug 14, 2026. Financial statements from company filings, amounts in US dollars.

    iSpecimen reported revenue of $1.93M for the fiscal year ended Dec 31, 2025, down 79.2% from the year before. That year, net income was -$10.49M with a net margin of -543.7%, operating cash flow was -$4.24M and free cash flow was -$5.24M. The quarter ended Jun 30, 2026 had revenue of $151.94K and net income of -$1.36M.

    Revenue and Margins

    Over the 7 years to Dec 2025, revenue fell from $4.39M, a compound annual decline of 11.1%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$1.93M-79.2%1.2%-465.4%-543.7%
    Dec 2024$9.29M-6.4%42.9%-137.0%-134.5%
    Dec 2023$9.93M-4.6%51.4%-112.5%-111.8%
    Dec 2022$10.40M-6.6%54.3%-97.9%-98.5%
    Dec 2021$11.14M+36.1%52.9%-53.2%-80.5%
    Dec 2020$8.18M+90.4%56.2%-29.4%-56.8%
    Dec 2019$4.30M-2.2%50.5%-90.3%-110.0%
    Dec 2018$4.39MN/A46.2%-76.4%-121.7%
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Revenue$1.93M$9.29M$9.93M$10.40M$11.14M$8.18M$4.30M$4.39M
    Cost of revenue$1.90M$5.30M$4.82M$4.76M$5.25M$3.59M$2.13M$2.36M
    Gross profit$24.11K$3.99M$5.11M$5.65M$5.89M$4.60M$2.17M$2.03M
    Research and development$246.98K$537.89K$1.03M$801.13K$573.91K$497.18K$993.33K$1.21M
    Operating income-$8.98M-$12.73M-$11.17M-$10.19M-$5.93M-$2.41M-$3.88M-$3.36M
    Net income-$10.49M-$12.50M-$11.10M-$10.25M-$8.96M-$4.65M-$4.73M-$5.35M
    EBITDA-$8.75M-$10.03M-$9.09M-$8.89M-$5.78M-$1.59M-$2.52MN/A
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$151.94K$156.01K$51.76K$106.59K$713.13K$1.06M$1.48M$2.66M$2.86M$2.29M$2.58M$2.78M
    Gross profit$68.65K$71.60K-$547.08K-$98.00K$268.96K$400.23K$151.35K$1.11M$1.44M$1.29M$1.15M$1.39M
    Operating income-$1.36M-$2.54M-$2.69M-$2.83M-$1.82M-$1.64M-$5.84M-$1.71M-$2.18M-$3.00M-$2.87M-$2.19M
    Net income-$1.36M-$2.28M-$5.00M-$2.78M-$1.05M-$1.66M-$6.05M-$1.44M-$2.11M-$2.90M-$3.07M-$2.11M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $56.92K by $6.82M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$9.53M$9.35M$15.82M$24.62M$35.72M$6.21M$4.21M$4.04M
    Current assets$6.95M$3.59M$8.24M$19.68M$32.95M$3.47M$1.58M$2.30M
    Cash and equivalents$6.88M$1.88M$2.34M$15.31M$27.74M$695.91K$53.89K$1.13M
    Total liabilities$6.44M$6.04M$6.08M$4.31M$5.93M$22.31M$26.93M$22.47M
    Short-term debt$56.92K$43.37K$167.11K$158.45KN/A$10.68M$10.59M$6.97M
    Long-term debtN/AN/AN/AN/A$3.42M$178.90KN/AN/A
    Shareholder equity$3.09M$3.31M$9.74M$20.31M$29.79M-$27.28M-$22.72M-$18.42M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$7.39M$6.61M$9.53M$9.00M$6.03M$6.84M$9.35M$11.26M$11.90M$12.51M$15.82M$16.30M
    Total liabilities$5.66M$5.80M$6.44M$5.92M$5.41M$5.17M$6.04M$6.55M$5.81M$5.70M$6.08M$3.59M
    Cash and equivalents$4.41M$2.82M$6.88M$2.78M$588.77K$782.56K$1.88M$1.75M$2.15M$2.09M$2.34M$2.72M
    Shareholder equity$1.74M$814.04K$3.09M$3.07M$621.97K$1.67M$3.31M$4.71M$6.09M$6.81M$9.74M$12.71M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$4.24M-$8.26M-$5.81M-$5.82M-$10.67M-$288.38K-$2.68M-$2.68M
    Capital expenditures$1.00M$684.83K$3.79M$3.19M$1.04M$1.10M$1.48M$1.03M
    Free cash flow-$5.24M-$8.95M-$9.59M-$9.01M-$11.71M-$1.39M-$4.16M-$3.71M
    Share repurchases$0$52.50K$0N/A$2.34MN/AN/AN/A
    Investing cash flow-$1.00M$1.98M-$7.23M-$3.19M-$1.04M-$1.10M-$1.48M-$1.03M
    Financing cash flow$10.24M$5.82M$70.89K-$3.42M$38.75M$2.03M$3.08M$3.52M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$689.63K-$3.36M-$916.92K-$2.04M-$192.23K-$1.10M-$3.57M-$1.08M-$1.54M-$2.07M$345.14K-$1.63M
    Capital expendituresN/A$700.00K$0$1.00M$454$0$73.06K$154.95K$172.20K$284.62K$266.13K$775.43K
    Free cash flowN/A-$4.06M-$916.92K-$3.04M-$192.69K-$1.10M-$3.65M-$1.23M-$1.71M-$2.36M$79.02K-$2.41M
    Last 12 quarters

    Frequently Asked Questions About ISPC

    What is iSpecimen's annual revenue?

    iSpecimen reported revenue of $1.93M for the fiscal year ended Dec 31, 2025.

    How fast is iSpecimen's revenue growing?

    Revenue was down 79.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -43.0%.

    Is iSpecimen profitable?

    No. iSpecimen reported net income of -$10.49M for the fiscal year ended Dec 31, 2025, with a net margin of -543.7%.

    How much free cash flow does ISPC generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$4.24M minus capital expenditures of $1.00M produced free cash flow of -$5.24M.

    How much debt does iSpecimen have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $56.92K and cash and equivalents of $6.88M.